Clinical Omics and Informatics Unit, Department of Medicine, Neuroscience Institute Observatory Western Cape 7925 University of Cape Town Faculty of Health Sciences
Auto-generated profile, based on publicly available information
Gideon Akuamoah Wiafe
Clinical Omics and Informatics Unit, Department of Medicine, Neuroscience Institute Observatory Western Cape 7925 University of Cape Town Faculty of Health Sciences
Diabetes mellitus (DM), a complex heterogeneous metabolic disorder characterized by a defect in the function of insulin, is on the rapid rise globally. Sustained hyperglycemia which is a major sign of DM is linked to the generation of reactive oxygen species which promotes adverse complications of the disorder. Traditional herbal treatment of DM is a common practice in Africa and other tropical parts of the world. Vernonia amygdalina (VA), one of the highly researched species in the Asteraceae family, has proven to possess potent antidiabetic properties. Several phytochemicals identified in multiple extracts from VA are purported to be responsible for the antidiabetic potential of the plant. In this review, we discuss the therapeutic potential of VA in diabetes and its associated complications. We appraise the current evidence and further suggest potential areas that could be effectively exploited in future VA research on diabetes.
9 November 2021 in International Journal of Developmental Neuroscience
Compound heterozygous SMN1 genotypes account for approximately 5% of spinal muscular atrophy (SMA) cases but are difficult to detect using conventional short-read sequencing due to near-identical homology between SMN1 and its paralog SMN2. We describe a patient with a decade-long diagnostic odyssey in whom whole exome and short-read whole genome sequencing failed to establish a diagnosis, despite a single SMN1 copy having been detected and dismissed as carrier status. The patient presented in childhood with progressive proximal limb weakness, tongue atrophy with fasciculations and electrophysiological evidence of chronic neurogenic disease. High-fidelity long-read whole genome sequencing resolved the SMN locus unambiguously, identifying a compound heterozygous genotype comprising an SMN1 gene deletion and a likely pathogenic missense variant (c.347 T>C; p.Ile116Thr) on the remaining allele, confirming SMA type 3. This case illustrates how long-read sequencing can resolve paralogous genomic regions intractable to short-read approaches, and highlights that a single detected SMN1 copy in a patient with a compatible phenotype warrants evaluation for a second sequence-level variant.
Following a confirmed genetic diagnosis, rare disease patients and their families encounter significant challenges in accessing diagnostic information and support. Patients and non-specialists are increasingly expected to interpret and share test results; however, existing standards are primarily designed for specialists. These standards fail to address the needs of resource-limited populations where low genomic literacy hampers accurate dissemination of genetic results. This research introduces RareInsight, an open-source, interactive dashboard designed to enhance the accessibility, comprehension, and collaboration of genetic data among patients, caregivers, clinicians, and researchers. Developed using shinydashboard, RareInsight was evaluated using whole exome sequencing data from skeletal dysplasia patients. It allows users to input and view Variant Call Format files and includes a searchable ClinVar variant table with filtering options, providing access to multiple resources based on search terms. RareInsight aims to simplify the dissemination of complex genetic information beyond the clinical setting. This dashboard serves as a pilot study demonstrating the potential of patient-centered interactive dashboards for the rare disease community.